of the Office of Disease Prevention and Health Promotion of the U.S. Public Health Service. The mission of the Task Force is to rigorously evaluate the effectiveness of clinical preventive services and to formulate recommendations for primary care clinicians regarding the appropriate content of periodic health examinations. The first Task Force concluded its work in 1989 with the publication of the Guide to Clinical Preventive Services (the Guide). A second Task Force, appointed in 1990, concluded its work with the release of the second edition of the Guide in December 1995. Programmatic responsibility for the Task Force was transferred to AHCPR in 1995. The 1995 edition of the Guide, evaluating common screening tests, counseling interventions, immunizations and chemoprophylaxis, is available on the Internet (www.ahcpr.gov/clinic) and through the U.S. Government Printing Office, (202) 512-1800 (refer to stock # 017-001-00525 - 8).

Members of the third Task Force will be asked to serve up to 5 years. They will meet quarterly for 1 to 2 day meetings in the Washington, DC area. The Task Force will work closely with other organizations, including the American College of Preventive Medicine, American Academy of Family Physicians, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, American College of Physicians, American Nurses Association, and the Canadian Task Force on the Periodic Health Examination.

Nominations for Third U.S. Preventive Services Task Force

Members of the third Task Force will be selected on the basis of: (1) clinical expertise in the primary health care of children and/or adults; (2) experience in critical evaluation of research and evidence-based methods; (3) expertise in disease prevention and health promotion; (4) national leadership within their field of expertise; (5) ability to work collaboratively with peers; and, (6) no substantial conflicts of interest that would impair the scientific integrity of the work of the Task Force. Some Task Force members without primary health care clinical experience may be selected based on their expertise in methodologic issues such as medical decision making, clinical epidemiology, health economics, and behavioral interventions. AHCPR particularly encourages nominations of women, members of minority populations, and persons with disabilities. Interested individuals and organizations may

nominate one or more qualified persons for membership on the Task Force. Nominations should include curricula vitae and should state that the nominee is willing to serve as a member of the Task Force. AHCPR will ask persons being considered for membership to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts, to permit evaluation of possibly significant conflicts of interest. It is anticipated that approximately 10–12 individuals will be invited to serve on the third Task Force.

Materials Submission and Deadline

To be considered for membership on the U.S. Preventive Services Task Force, written nominations should be submitted by March 9, 1998 to: Douglas B. Kamerow, M.D., M.P.H., Director, Center for Practice and Technology Assessment, Agency for Health Care Policy and Research, 6000 Executive Boulevard, Willco Building, Suite 310, Rockville, Maryland 20852.

Responses will be available for inspection at the Center for Practice and Technology Assessment, telephone (301) 594–4015, weekdays between 8:30 a.m. and 5:00 p.m. AHCPR will not reply to individual responses, but will consider all nominations in selecting members.

For Additional Information

Additional information about the U.S. Preventive Services Task Force may be obtained by contacting: David Atkins, M.D., M.P.H., Center for Practice and Technology Assessment, Agency for Health Care Policy and Research, 6000 Executive Boulevard, Willco Building, Suite 310, Rockville, Maryland 20852; telephone (301) 594–4015; fax (301) 594–4027; *E-mail address:* datkins@abcpr.gov.

Dated: December 29, 1997.

John M. Eisenberg,

Administrator.

[FR Doc. 98–319 Filed 1–6–98; 8:45 am] BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Center for Scientific Review Special Emphasis Panel (SEP) meetings: *Purpose/Agenda:* To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: January 23, 1998.

Time: 4:00 p.m.

Place: NIH, Rockledge 2, Room 4148, Telephone Conference.

Contact Person: Dr. Philip Perkins, Scientific Review Administrator, 6701 Rockledge Drive, Room 4148, Bethesda, Maryland 20892, (301) 435–1718.

Name of SEP: Chemistry and Related Sciences.

Date: February 25, 1998.

Time: 12:00 p.m.

Place: NIH, Rockledge 2, Room 5152,

Telephone Conference.

Contact Person: Dr. Jean D. Sipe, Scientific Review Administrator, 6701 Rockledge Drive, Room 5152, Bethesda, Maryland 20892, (301) 435–1743.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: December 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–293 Filed 1–6–98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Efficacy of Mammography Screening Ages 40–49 Eurotrial 40 Telephone Conference Call.

Date: January 13, 1998.

Time: 1:00 p.m. to Adjournment. Place: National Cancer Institute, Executive Plaza North, Room 636B, 6130 Executive Boulevard, Bethesda, MD 20892.

Contact Person: Ray Bramhall, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 636B, 6130 Executive Boulevard, MSC 7407, Bethesda, MD 20892–7407, Telephone 301/496–3428. *Purpose/Agenda:* To review, discuss and evaluate grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: December 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–301 Filed 1–6–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Initial Review Group (IRG) meeting:

Name of IRG: Clinical Trials Review Committee.

Date: February 23, 1998.

Time: 8:00 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, Maryland 20814.

Contact Person: Dr. Joyce A. Hunter, 6701 Rockledge Drive, Rm. 7192, MSC 7924, Bethesda, Maryland 20892, (301) 435–0287.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93,838, Lung Diseases Research, and 93.839, Blood Diseases and Resources Research, National Institutes of Health) Dated: December 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–294 Filed 1–6–98; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting of the National Heart, Lung, and Blood Advisory Council

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the National Heart, Lung, and Blood Advisory Council, February 12–13, 1998, National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 10, Bethesda, Maryland.

The Council meeting will be open to the public on February 12 from 8:30 a.m. to approximately 3:00 p.m. for discussion of program policies and issues. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C., 10(d) of Pub. L. 92-463, the meeting will be closed to the public from approximately 3:00 p.m. on February 12 to adjournment on February 13, for the review, discussion, and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

Dr. Ronald G. Geller, Executive Secretary, National Heart, Lung, and Blood Advisory Council, Rockledge Building (RKL2), Room 7100, National Institutes of Health, Bethesda, Maryland 20892, (301) 435–0260, will furnish substantive program information.

(Catalog of Federal Domestic Assistance Program Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health) Dated: December 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 98–295 Filed 1–6–98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meetings:

Name of SEP: Central Lipid Laboratory for National Health and Nutrition Survey.

Date: January 29, 1998.

Time: 8:00 a.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: Jon Ranhand, Ph.D., Two Rockledge Center, Room 7188, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0280.

Purpose/Agenda: To review and evaluate contract proposals.

Name of SEP: Oxidation, Vascular Cell Function, and Atherosclerosis.

Date: February 9, 1998.

Time: 7:30 p.m.

Place: Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: Louis Ouellette, Ph.D., Two Rockledge Center, Room 7216, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0310.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Review of Independent Scientist Awards (K02s) and Mentored Clinical Scientist Development Awards (K08s).

Date: February 9, 1998.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: S. Charles Selden, Ph.D., Two Rockledge Center, Room 7196, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0288.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: CATCH 4 (R18s). Date: February 10–11, 1998.

Time: 9:00 a.m.

Place: Washington National Hilton, 2399 Jefferson Davis Highway, Arlington, Virginia 22202

Contact Person: Louise Corman, Ph.D., Two Rockledge Center, Room 7180, 6701 Rockledge Drive, MSC 7924, Bethesda, MD 20892–7924, (301) 435–0270.